Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SUPT16H

Gene summary for SUPT16H

Gene summary.

Gene information	Species	Human
	Gene symbol	SUPT16H
	Gene ID	11198
	Gene name	SPT16 homolog, facilitates chromatin remodeling subunit
	Gene Alias	CDC68
	Cytomap	14q11.2
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	Q9Y5B9

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
11198	SUPT16H	LZE21T	Human	Esophagus	ESCC	3.41e-07	4.19e-01	0.0655
11198	SUPT16H	LZE6T	Human	Esophagus	ESCC	1.11e-05	4.26e-01	0.0845
11198	SUPT16H	P1T-E	Human	Esophagus	ESCC	6.17e-11	6.34e-01	0.0875
11198	SUPT16H	P2T-E	Human	Esophagus	ESCC	6.77e-50	8.57e-01	0.1177
11198	SUPT16H	P4T-E	Human	Esophagus	ESCC	9.49e-35	9.55e-01	0.1323
11198	SUPT16H	P5T-E	Human	Esophagus	ESCC	3.12e-28	7.19e-01	0.1327
11198	SUPT16H	P8T-E	Human	Esophagus	ESCC	2.29e-40	7.91e-01	0.0889
11198	SUPT16H	P9T-E	Human	Esophagus	ESCC	6.84e-27	5.03e-01	0.1131
11198	SUPT16H	P10T-E	Human	Esophagus	ESCC	1.86e-61	1.20e+00	0.116
11198	SUPT16H	P11T-E	Human	Esophagus	ESCC	8.51e-22	8.54e-01	0.1426
11198	SUPT16H	P12T-E	Human	Esophagus	ESCC	2.76e-70	1.25e+00	0.1122
11198	SUPT16H	P15T-E	Human	Esophagus	ESCC	7.49e-65	1.43e+00	0.1149
11198	SUPT16H	P16T-E	Human	Esophagus	ESCC	1.10e-42	7.84e-01	0.1153
11198	SUPT16H	P17T-E	Human	Esophagus	ESCC	4.96e-17	9.08e-01	0.1278
11198	SUPT16H	P19T-E	Human	Esophagus	ESCC	3.81e-07	6.62e-01	0.1662
11198	SUPT16H	P20T-E	Human	Esophagus	ESCC	6.72e-17	3.80e-01	0.1124
11198	SUPT16H	P21T-E	Human	Esophagus	ESCC	6.95e-40	7.29e-01	0.1617
11198	SUPT16H	P22T-E	Human	Esophagus	ESCC	7.17e-49	9.48e-01	0.1236
11198	SUPT16H	P23T-E	Human	Esophagus	ESCC	4.11e-35	9.08e-01	0.108
11198	SUPT16H	P24T-E	Human	Esophagus	ESCC	2.09e-21	5.55e-01	0.1287

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0022411	Colorectum	AD	cellular component disassembly	147/3918	443/18723	8.53e-10	6.76e-08	147
GO:0032984	Colorectum	AD	protein-containing complex disassembly	81/3918	224/18723	9.41e-08	4.65e-06	81
GO:0006325	Colorectum	AD	chromatin organization	119/3918	409/18723	4.85e-05	8.33e-04	119
GO:0032986	Colorectum	AD	protein-DNA complex disassembly	12/3918	20/18723	1.60e-04	2.21e-03	12
GO:0031498	Colorectum	AD	chromatin disassembly	11/3918	20/18723	8.39e-04	8.21e-03	11
GO:0006337	Colorectum	AD	nucleosome disassembly	10/3918	18/18723	1.31e-03	1.15e-02	10
GO:0032786	Colorectum	AD	positive regulation of DNA-templated transcription, elongation	13/3918	27/18723	1.47e-03	1.25e-02	13
GO:0006354	Colorectum	AD	DNA-templated transcription, elongation	31/3918	91/18723	2.46e-03	1.90e-02	31
GO:0006368	Colorectum	AD	transcription elongation from RNA polymerase II promoter	24/3918	69/18723	5.35e-03	3.52e-02	24
GO:0006338	Colorectum	AD	chromatin remodeling	70/3918	255/18723	7.44e-03	4.53e-02	70
GO:00224112	Colorectum	MSS	cellular component disassembly	130/3467	443/18723	1.44e-08	8.46e-07	130
GO:00329842	Colorectum	MSS	protein-containing complex disassembly	69/3467	224/18723	5.61e-06	1.50e-04	69
GO:00329862	Colorectum	MSS	protein-DNA complex disassembly	12/3467	20/18723	4.55e-05	8.35e-04	12
GO:00063252	Colorectum	MSS	chromatin organization	107/3467	409/18723	7.22e-05	1.21e-03	107
GO:00314982	Colorectum	MSS	chromatin disassembly	11/3467	20/18723	2.77e-04	3.67e-03	11
GO:00063371	Colorectum	MSS	nucleosome disassembly	10/3467	18/18723	4.76e-04	5.58e-03	10
GO:00063541	Colorectum	MSS	DNA-templated transcription, elongation	29/3467	91/18723	1.52e-03	1.39e-02	29
GO:00327861	Colorectum	MSS	positive regulation of DNA-templated transcription, elongation	12/3467	27/18723	1.74e-03	1.55e-02	12
GO:00063681	Colorectum	MSS	transcription elongation from RNA polymerase II promoter	22/3467	69/18723	5.31e-03	3.62e-02	22
GO:00224114	Colorectum	FAP	cellular component disassembly	97/2622	443/18723	3.44e-06	1.23e-04	97

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SUPT16H

SNV

Missense_Mutation

novel

c.121N>C

p.Asp41His

p.D41H

Q9Y5B9

protein_coding

deleterious(0)

probably_damaging(0.962)

TCGA-3C-AALI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Poly E

Complete Response

SUPT16H

SNV

Missense_Mutation

novel

c.1921G>A

p.Glu641Lys

p.E641K

Q9Y5B9

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

SUPT16H

SNV

Missense_Mutation

c.1444G>C

p.Ala482Pro

p.A482P

Q9Y5B9

protein_coding

tolerated(0.14)

possibly_damaging(0.759)

TCGA-A8-A09A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

SUPT16H

SNV

Missense_Mutation

c.594N>A

p.Phe198Leu

p.F198L

Q9Y5B9

protein_coding

tolerated(1)

benign(0.003)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SUPT16H

SNV

Missense_Mutation

novel

c.535N>A

p.Glu179Lys

p.E179K

Q9Y5B9

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SUPT16H

SNV

Missense_Mutation

novel

c.296G>C

p.Gly99Ala

p.G99A

Q9Y5B9

protein_coding

tolerated(0.09)

benign(0.147)

TCGA-BH-A0B6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SUPT16H

SNV

Missense_Mutation

novel

c.2806N>A

p.Glu936Lys

p.E936K

Q9Y5B9

protein_coding

tolerated(0.2)

benign(0.011)

TCGA-C8-A8HQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SUPT16H

SNV

Missense_Mutation

c.905N>G

p.Tyr302Cys

p.Y302C

Q9Y5B9

protein_coding

deleterious(0)

possibly_damaging(0.877)

TCGA-D8-A1JH-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

nolvadex

SUPT16H

SNV

Missense_Mutation

c.991N>T

p.Asp331Tyr

p.D331Y

Q9Y5B9

protein_coding

deleterious(0.01)

possibly_damaging(0.827)

TCGA-E9-A1RG-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

tamoxiphen

SUPT16H

SNV

Missense_Mutation

c.441G>A

p.Met147Ile

p.M147I

Q9Y5B9

protein_coding

tolerated(0.81)

benign(0.011)

TCGA-GM-A2D9-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1